Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Study Design
- Randomized, double-blind, placebo-controlled, escalating single-dose design.
- Six ascending dose cohorts
- In each cohorts, subjects will be randomized to receive a single dose of HM10460A,
placebo (negative control), or Neulasta® (positive control).
- Primary Objective
- to assess the safety and tolerability of single escalating subcutaneous doses of
HM10460A in healthy adult Japanese and Caucasian subjects.